Profusa’s Five Pillars of Growth in the Red-Hot Wearables Market
Health tech innovator merges clinical ambition with crypto finance as global wearable demand surges.
Profusa (NASDAQ: PFSA) is moving fast to cement its position in the rapidly expanding wearables industry, unveiling a five-pillar growth strategy that spans advanced health monitoring, artificial intelligence, and even Bitcoin (BTCUSD) treasury management. With its Lumee™ Oxygen platform already aimed at a $10 billion global market, the company is also taking a bold step into the world of digital assets, a move more common among tech giants and crypto miners than medical device makers.
The five pillars, revenue growth and pipeline development, AI infrastructure, clinical and regulatory pathways, financial structure, and scaling operations, form the backbone of Profusa’s roadmap.
Profusa Chairman and CEO Ben Hwang, Ph.D., explained:
As we advance our programs, we have established five pillars that we believe will encompass our growth strategy, which we will use to guide our progress and shape our message. … We believe that organizing our activities in this way will help us best achieve our goals and ultimately maximize our shareholder value.
Wearables Sector Heats Up
Profusa’s expansion comes at a time when wearable technology is booming. The global market, valued at USD $86.78 billion in 2025, is projected to more than double to USD $191.58 billion by 2032. The surge is fueled by rising health consciousness, AI-powered sensors, and remote monitoring capabilities.
The space is already generating dramatic gains for investors. Zepp Health (NYSE: ZEPP) has soared over 800% in the past month, driven by revenue growth, new product launches, and its premium Amazfit brand. Know Labs (NYSE American: KNW), an industry-leading technology company developing transformative financial services and non-invasive health monitoring solutions, recently announced the closing of a $125 million acquisition by Greg Kidd, bringing in 1,000 Bitcoin and rebranding to USBC, Inc., with a pivot toward blockchain-powered digital currency. Vuzix (NASDAQ: VUZI), a leading supplier of AI-powered smart glasses, waveguides and augmented reality tech, also saw its stock jump last week after securing a six-figure smart glasses follow-on order from LogistiVIEW.
These companies, along with sector leaders like Apple (NASDAQ: AAPL), Alphabet (NASDAQ: GOOGL), Garmin (NYSE: GRMN), Sony (NYSE: SONY), Samsung (OTC: SSNLF), and Xiaomi (OTC: XIACF), are competing for market share in a field that’s rapidly evolving beyond step counters and calorie trackers. Today’s wearables can measure blood oxygen, track glucose levels, and deliver AI-driven coaching, exactly the space where Profusa plans to lead.
Pillar One: Revenue Growth and Pipeline Development
Profusa is on its way to generating revenue from research-use-only applications of its biosensor technology, which continuously monitors biochemical markers in the body. These applications are poised to not only bring in cash but also push the platform’s capabilities further.
The company’s near-term commercial focus is on tissue oxygen monitoring, targeting indications such as peripheral artery disease, chronic wounds, and critical limb ischemia. With CE mark approval in hand, Profusa signed a distribution agreement with Spain’s Dismeval, S.L., aiming for a Q1 2026 European launch. The company pegs its total addressable market for tissue oxygen monitoring at $10 billion globally, with roughly 300,000 endovascular procedures performed annually in Europe alone.
Profusa also plans to commercialize its continuous glucose monitoring platform, which has a total global addressable market of more than 500 million patients, with pivotal studies expected in 2026 and a target mid-2027 launch.
Pillar Two: AI Infrastructure
Profusa’s sensors feed data into an AI-powered analytics platform capable of delivering personalized insights for patients and healthcare providers. This integration could enable coaching, predictive alerts, and optimization of treatment strategies, moving wearables from passive tracking devices to active health management tools.
By embedding AI into the platform from the start, Profusa positions itself to ride the next wave of digital health, where devices don’t just measure but also interpret and guide.
Pillar Three: Clinical and Regulatory Pathways
The Lumee Oxygen platform’s CE mark gives Profusa an early foothold in Europe, but the U.S. market remains a critical prize. The company expects to launch a pivotal U.S. clinical study alongside its EU rollout in 2026, with FDA submission mid-year and potential commercialization in 2027.
For glucose monitoring, ongoing human validation studies at two EU and two APAC sites are expected to produce peer-reviewed data soon, paving the way for pivotal trials.
Pillar Four: Financial Structure and Strategies
Profusa’s financial pillar took an unexpected turn into the digital asset arena. On July 21, the company secured a $100 million equity line of credit with Ascent Partners Fund LLC, committing all proceeds to Bitcoin purchases, provided its cash balance exceeds $5 million at the time of each transaction.
Last month, Profusa made its first $1 million Bitcoin purchase through BlockFills, joining high-profile corporate adopters like Strategy (NASDAQ: MSTR), MARA Holdings (NASDAQ: MARA), and Trump Media (NASDAQ: DJT).
Hwang called it:
An important first step in our collaboration with Ascent Partners Fund to establish a low-cost, capital-efficient, best-of-breed Bitcoin treasury strategy reflecting our strong conviction in Bitcoin as the digital store of value for the future and our dedication to driving our healthcare programs forward.
The move puts Profusa in the middle of a corporate trend that has seen more than 791,000 BTC, about 4% of the total supply, held on public company balance sheets. Some firms, like BitMine Immersion (NYSE American: BMNR) and others, are also adding Ethereum (ETHUSD) to their reserves.
Pillar Five: Scaling Operations
Profusa is building the manufacturing and distribution capacity needed to meet demand once its products hit the commercial market. That means ensuring its operations can scale rapidly across multiple geographies while maintaining quality and regulatory compliance.
The long-term vision is ambitious: a single injected biosensor capable of delivering continuous, medical-grade biochemical data across multiple indications. If successful, this could redefine how chronic and acute conditions are monitored and treated.
At the Intersection of Health and Finance
Profusa’s strategy blends two high-growth narratives, the digitization of healthcare and the rise of corporate crypto treasuries. The combination is rare, but it reflects the company’s belief that innovation must extend beyond the lab into how it funds and scales its vision.
By aligning its financial reserves with Bitcoin, Profusa is signaling both confidence in decentralized finance and a willingness to stand alongside bold market movers. At the same time, its clinical ambitions keep it rooted in one of the fastest-growing segments of medical technology.
For investors, that dual focus could make Profusa a unique play in both the wearables and crypto markets. With a $10 billion addressable market for oxygen monitoring, a 500-million-patient target for glucose tracking, and a balance sheet strategy inspired by some of the biggest names in Bitcoin, the company is betting its five pillars will support more than just growth; they’ll drive transformation.
As Hwang told shareholders:
We believe we hold the keys to a bright future where a tiny filament injected subcutaneously can provide a wealth of information across an array of indications, and are confident that our five pillars will provide the organization necessary to help us drive forward in a focused manner.
Also Read: Profusa Expands into Europe and Bitcoin, Joins Wall Street’s Digital Treasury Movement
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at: invest@wealthyvc.com.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. WealthyVC and our controlling entity 1000724287 Ontario Ltd., have been compensated USD $125,000 for six months for investor relations by Profusa, Inc. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
